LGALS9 and airway hyperresponsiveness: After the administration of an allergen-specific sublingual immunotherapy, mice receiving adjuvant Gal-9 showed an improved airway hyperresponsiveness along with a significant reduction in IL-5, IL-13, and IgE BAL and blood concentrations, demonstrating the potential role of Gal-9 as a treatable trait for both allergic and eosinophilic asthma inflammation [37].